Punia Vineet, Byrnes MarieElena, Thompson Nicolas R, Ayub Neishay, Rubinos Clio, Zafar Sahar, Sivaraju Adithya, Ying Zhong, Fesler Jessica R, Hantus Stephen
Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Ann Clin Transl Neurol. 2025 Jun;12(6):1225-1239. doi: 10.1002/acn3.70039. Epub 2025 Apr 17.
Post-discharge management and outcomes of acute symptomatic seizures (ASyS) remain underexplored. We analyzed post-discharge ASM management and outcomes in ASyS patients undergoing continuous EEG (cEEG), including the role of outpatient care through a post-acute symptomatic seizure (PASS) clinic.
We performed a single-center, retrospective study of adults without epilepsy discharged on ASMs due to witnessed or suspected ASyS in 2019. A cause-specific cumulative distribution function was used to estimate outcome probabilities, and cause-specific Cox proportional hazards models examined factors influencing the first ASM discontinuation, subsequent unprovoked seizure, and death.
The study evaluated 307 patients [mean 61.6 years; 51.8% females], 60.2% with confirmed ASyS [144 (46.9%) clinical ASyS; 41 (13.4%) with electrographic ASyS only]. During median 14-month follow-up, 31.9% discontinued ASM, 18.6% experienced unprovoked seizure, and 38.4% died. Based on cumulative incidence function, ASM discontinuation, unprovoked seizure, and death at 12 months occurred in 26.2%, 14.1%, and 29.3% of patients, respectively. 59.6% of alive patients without unprovoked seizures were taking ASMs. Clinical ASyS (HR 0.48; 95% CI 0.31, 0.76), electrographic ASyS only (HR 0.37; 0.17, 0.82), and acute epileptiform abnormalities (HR 0.48; 0.27, 0.84) were associated with lower ASM discontinuation. Unprovoked seizures were associated with epileptiform outpatient EEG (HR 5.40; 2.62, 11.12). PASS clinic patients discontinued ASMs 74% faster (HR 1.74; 1.12, 2.71), with 88% lower risk of unprovoked seizures (HR 0.12; 0.04, 0.34).
Outpatient ASM overuse in ASyS patients is common. Outpatient epileptiform abnormalities may predict unprovoked seizures. Structured outpatient care, such as PASS clinics, facilitates faster yet safer ASM discontinuation.
急性症状性癫痫发作(ASyS)出院后的管理及结局仍未得到充分研究。我们分析了接受持续脑电图(cEEG)监测的ASyS患者出院后抗癫痫药物(ASM)的管理及结局,包括通过急性症状性癫痫发作后(PASS)门诊进行门诊护理的作用。
我们对2019年因目睹或疑似ASyS而在出院时接受ASM治疗的无癫痫成年患者进行了一项单中心回顾性研究。使用特定病因累积分布函数来估计结局概率,并使用特定病因Cox比例风险模型检查影响首次停用ASM、随后的无诱因癫痫发作和死亡的因素。
该研究评估了(307)例患者(平均年龄(61.6)岁;女性占(51.8%)),其中(60.2%)确诊为 ASyS((144)例((46.9%))为临床ASyS;(41)例((13.4%))仅为脑电图ASyS)。在中位(14)个月的随访期间,(31.9%)的患者停用了ASM,(18.6%)的患者经历了无诱因癫痫发作,(38.4%)的患者死亡。根据累积发病率函数,在(12)个月时,分别有(26.2%)、(14.1%)和(29.3%)的患者停用了ASM、经历了无诱因癫痫发作和死亡。在没有无诱因癫痫发作的存活患者中,(59.6%)仍在服用ASM。临床ASyS(风险比(HR)(0.48);(95%)置信区间(CI)(0.31),(0.76))、仅脑电图ASyS(HR (0.37);(0.17),(0.82))和急性癫痫样异常(HR (0.48);(0.27),(0.84))与较低的ASM停用率相关。无诱因癫痫发作与门诊脑电图癫痫样异常相关(HR (5.40);(2.62),(11.12))。PASS门诊患者停用ASM的速度快(74%)(HR (1.74);(1.12),(2.71)),无诱因癫痫发作风险降低(88%)(HR (0.12);(0.04),(0.34))。
ASyS患者门诊ASM过度使用很常见。门诊癫痫样异常可能预测无诱因癫痫发作。结构化门诊护理,如PASS门诊,有助于更快且更安全地停用ASM。